Hexarelin

Hexarelin (also called examorelin) is a potent synthetic hexapeptide growth hormone secretagogue that binds two distinct receptors: GHS-R1a (the ghrelin receptor — drives endogenous GH release) and CD36 (a scavenger receptor on cardiomyocytes — drives cardioprotective effects). It is the most potent of the classical GHRPs on a per-molecule basis, producing the highest peak GH pulse amplitude at equivalent doses. However, this potency comes with the strongest HPA axis cross-reactivity among GHRPs — meaningful cortisol, prolactin, and ACTH elevation — and the fastest GHS-R1a receptor desensitization. It is not FDA-approved; research use is typically SC injection 100-200 mcg 1-2 times daily in short (4-6 week) cycles.

All three are GHS-R1a agonists but with different selectivity profiles. Hexarelin has the highest GH-release potency but the highest HPA cross-reactivity (cortisol +30-50%, meaningful ACTH and prolactin elevation) and fastest receptor desensitization. GHRP-2 has strong GH potency with modest HPA effects (+15-25% cortisol). Ipamorelin has good GH potency with minimal HPA effects (negligible cortisol, prolactin, ACTH impact). Practical implication: hexarelin for short aggressive 4-6 week phases where peak GH pulse matters; GHRP-2 for medium-duration use; ipamorelin for chronic clean daily use. Hexarelin is uniquely able to bind CD36, which drives its cardioprotective research interest — a property neither GHRP-2 nor ipamorelin share.

Standard SC protocol is 100-200 mcg per injection, 1-2 times daily (pre-breakfast and pre-bed), cycled 4-6 weeks on with 2-4 weeks off. Beginners start at 100 mcg once daily (pre-bed only) to assess tolerance before escalating. Intermediate users run 150-200 mcg twice daily. The single-injection ceiling is approximately 200 mcg — above this, receptor saturation prevents additional GH release while cortisol continues to rise proportionally. Hexarelin should not be used continuously longer than 6-8 weeks because receptor desensitization attenuates GH response and cumulative cortisol/prolactin exposure becomes meaningful. Always dose fasted (2-3 hours after last meal) to avoid glucose/insulin-driven somatostatin blunting of GH release.

Yes — hexarelin produces the most pronounced cortisol elevation of any commonly-used GHS compound, typically +30-50% above baseline in the 60-90 minute post-injection window, versus +15-25% for GHRP-2/GHRP-6 and negligible effects for ipamorelin. Hexarelin also meaningfully elevates ACTH, which other GHRPs do not. Per single dose, this is usually clinically trivial in healthy users. Cumulative chronic exposure matters more — which is why hexarelin is recommended for short 4-6 week cycles rather than continuous long-term use. Users with baseline anxiety, HPA axis concerns, insomnia, or mood disorders should use ipamorelin instead of hexarelin. Cortisol monitoring on labs (baseline and end-of-cycle) is important for hexarelin specifically.

Hexarelin binds CD36, a scavenger receptor expressed on cardiomyocytes and macrophages. Preclinical research in animal models documents reduced infarct size following ischemia-reperfusion insult, improved ventricular contractility in cardiomyopathy models, anti-inflammatory effects at vascular endothelium, and favorable cardiac remodeling after experimental myocardial infarction (Torsello 2003 and subsequent work). These effects are mechanistically independent of the GH/IGF-1 axis — hexarelin produces cardiac protection even when GHS-R1a is blocked. Clinical translation to human cardiac therapy has not occurred; no validated cardiac indication exists. The cardiac research interest is genuine but doesn't support self-experimentation in cardiovascular disease — specialist-supervised research protocols only.

Yes, selectively. The most pharmacologically significant stack is hexarelin + GHRH analog (sermorelin, CJC-1295 no-DAC, or tesamorelin) in the same injection — produces the largest GH pulses of any common peptide combination, appropriate for short 4-6 week intensive phases. Hexarelin also stacks well with BPC-157 and TB-500 for tissue repair during aggressive training cycles, and with testosterone replacement for additive anabolic effects. AVOID stacking hexarelin with other GHS-R1a agonists (GHRP-2, GHRP-6, ipamorelin, MK-677) — they are mechanistically redundant. Also avoid stacking with glucocorticoids, high-dose stimulants, or GLP-1 agonists during active weight loss phases. Hexarelin is the GHS compound most sensitive to bad stacking choices because of the HPA cross-reactivity.

Common effects: pronounced facial flushing and warmth post-injection (stronger than other GHRPs), injection site reactions, cortisol elevation (+30-50% above baseline for 60-90 min), prolactin elevation, intermediate appetite stimulation, and vivid dreams with bedtime dosing. Less common: headache (more frequent than with other GHRPs), mild nausea, transient hypotension with IV administration, fluid retention in first weeks, insulin sensitivity reduction with chronic use. The HPA axis effects are the distinguishing hexarelin signature — ACTH elevation that other GHRPs do not cause. Long-term theoretical concerns include cumulative cortisol exposure contributing to HPA dysregulation, insulin resistance, and sustained IGF-1 elevation. Short cycling (4-6 weeks) minimizes these concerns significantly.

Hexarelin is not FDA-approved for any indication in the United States. It has been studied in European clinical trials for GH deficiency diagnostic testing and cardiac research. Research-grade hexarelin is sold through peptide research suppliers under research-only classification. Users should understand this legal context, source from vendors with third-party purity testing, and ideally work with a practitioner familiar with peptide therapy. Some 503B compounding pharmacies include hexarelin in their offerings for physician-supervised off-label use, though it's less commonly compounded than ipamorelin or GHRP-2. See our best vendors guide for reliable sources and peptide-friendly clinical practices.

Hexarelin produces more rapid GHS-R1a receptor desensitization than GHRP-2, GHRP-6, or ipamorelin. Within 4-8 weeks of continuous daily dosing, GH response measurably attenuates — you get smaller GH pulses for the same dose. Dose escalation to overcome this attenuation disproportionately increases cortisol and prolactin exposure rather than restoring GH output. The pharmacologically sensible response is to cycle: 4-6 weeks on, then 2-4 weeks off, allowing the receptor to resensitize. Other GHRPs maintain responsiveness for 12+ weeks before cycling is strictly needed. This cycling requirement is why hexarelin is better positioned as a situational short-cycle tool than as a chronic daily compound — ipamorelin or low-dose GHRP-2 are better for continuous long-term GH support.

Most modern peptide protocols favor ipamorelin for the majority of bodybuilding use cases because: (1) it can be used continuously for 12+ weeks without meaningful receptor desensitization, (2) it has minimal HPA cross-reactivity, (3) it has minimal appetite effect (useful during cutting), and (4) its longer half-life (~2 hours vs hexarelin's 15-30 minutes) provides more sustained coverage. Hexarelin has a legitimate role in short 4-6 week intensive anabolic phases where maximum peak GH pulse matters more than cortisol cleanliness — typically stacked with CJC-1295 no-DAC and testosterone replacement. After a hexarelin phase, transition back to ipamorelin for maintenance and cut phases. Using hexarelin continuously for bodybuilding is a common mistake that produces diminishing GH returns and accumulating cortisol exposure. See ipamorelin for detailed use-case comparison.